8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Feb 19, 2026·SEC
Rein Therapeutics Inc.(RNTX)Earnings, Financials & Key Ratios
RNTX•NASDAQ
$0.97
Price updated Jun 27, 2026
AboutRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.Show more
- Revenue$0
- EBITDA-$22M+66.3%
- Net Income-$50M+20.7%
- EPS (Diluted)-1.96+44.2%
- ROE-139.87%+31.8%
RNTX Price & Volume
Rein Therapeutics Inc. (RNTX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Burn Threatens Corporate Solvency
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity shortfall
"Rein Therapeutics is currently navigating a high-risk transition into capital-intensive clinical development, characterized by a complete lack of commercial revenue and escalating R&D expenditures. The company's financial foundation has rapidly eroded, with total assets contracting from $109.4M in 2024Q2 to $26.3M in 2026Q1, while accumulated losses have ballooned to over $407M. Investors should monitor the critical liquidity shortfall, as the current $3.2M cash balance and a 0.40 current ratio suggest an urgent need for dilutive financing to sustain operations."
Verdict Logic
Negative: The company faces an imminent liquidity crisis with a current ratio of 0.40 and a consistent quarterly cash burn that threatens its ability to operate as a going concern.
RNTX Growth Metrics
Rein Therapeutics Inc. (RNTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM4.07%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM33.33%
Return on Capital
10 Years-22.18%
5 Years-26.58%
3 Years-44.25%
Last Year-53.84%
RNTX Recent Earnings
Rein Therapeutics Inc. (RNTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.19+61.2%
$0.49
Rev
—
—
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$1.09+0.0%
$1.09
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.21+12.5%
$0.24
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.28-27.3%
$0.22
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.19vs $0.49+61.2% | — |
| Q2 2026 | Mar 26, 2026 | $1.09vs $1.09+0.0% | — |
| Q4 2025 | Nov 14, 2025 | $0.21vs $0.24+12.5% | — |
| Q3 2025 | Aug 14, 2025 | $0.28vs $0.22-27.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Rein Therapeutics Inc. (RNTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.97 | $27.15M | -0.50 | — | — | -139.87% | — | |
| $0.28 | $922.59K | -0.30 | — | -124.79% | -85.83% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $23.57 | $1.74B | 7.14 | 18.52% | 118.91% | 47.59% | — | |
| $1.64 | $5.99M | -1.16 | -100% | — | -102.06% | — | |
| $103.38 | $22.41B | -16.13 | 66.73% | -144.44% | -130.11% | — |
Compare RNTX vs Peers
Rein Therapeutics Inc. (RNTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RNTX SEC Filings & Documents
Rein Therapeutics Inc. (RNTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when RNTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RNTX Frequently Asked Questions
Rein Therapeutics Inc. (RNTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is RNTX profitable?
Rein Therapeutics Inc. (RNTX) reported a net loss of $50.2M for fiscal year 2025.
Dividend & Returns
What is RNTX's return on equity?
Rein Therapeutics Inc. (RNTX) has a return on equity (ROE) of -139.9%. Negative ROE indicates the company is unprofitable.
What is Rein Therapeutics Inc.'s free cash flow?
Rein Therapeutics Inc. (RNTX) had negative free cash flow of $16.6M in fiscal year 2025, likely due to heavy capital investments.